Epizyme

Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them.

Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

Revenue(FY, 2016)

$8 M

Market capitalization(2017-10-20)

$995.3 M

Company Growth (employees)

Type

Public

Cambridge, US

Founded

2007

Size (employees)

112 (est)+26%

Website

epizyme.com

Epizyme was founded in 2007 and is headquartered in Cambridge, US

Key People/Management at Epizyme

Robert A. Copeland

Executive Vice President and Chief Scientific Officer

Epizyme Office Locations

Epizyme has an office in Cambridge

Cambridge, US (HQ)

400 Technology Square

Epizyme Financials and Metrics

Epizyme Financials

Epizyme's revenue was reported to be $8 m in FY, 2016

Summary

USD

Epizyme's current market capitalization is $995.3 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	68.5 m	41.4 m	2.6 m	8 m
Revenue growth, %		(40%)	(94%)	213%
R&D expense				91.5 m
General and administrative expense				28.4 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
R&D expense	17.5 m	22.2 m	57.1 m	20.6 m	16.8 m	17.7 m	21.5 m	23.9 m	24.7 m
General and administrative expense	5.3 m	5.7 m	5.2 m	6 m	6.7 m	5.8 m	7.4 m	7.5 m	8.3 m
Operating expense total	22.8 m	27.9 m	62.3 m	26.5 m	23.5 m	23.6 m	28.9 m	31.4 m	33 m
EBIT	(13.3 m)	(19.7 m)	(61.4 m)	(25.8 m)	(23.1 m)	(23.1 m)	(28.4 m)	(24.8 m)	(33 m)

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	123.6 m	190.1 m	208.3 m	77.9 m
Accounts Receivable	33.7 m	2.1 m	262 k	23 k
Inventories	2.4 m	2.8 m	4.5 m	6.5 m
Current Assets	159.7 m	195 m	213.1 m	248.7 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Cash	229.9 m	211.7 m	244.5 m	236.7 m	229.9 m	312.7 m	89.5 m	66 m	64.4 m
Accounts Receivable	2.2 m	2.1 m	365 k	723 k	177 k	176 k	60 k	6.2 m	8 k
Current Assets	234.7 m	217.1 m	247.4 m	239.4 m	232.6 m	318.3 m	296.6 m	275 m	220 m
PP&E	2.6 m	2.7 m	5.2 m	4.9 m	4.5 m	3.8 m	3.6 m	3.3 m	3.3 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(3.5 m)	(55 m)	(132.4 m)	(110.2 m)
Depreciation and Amortization	703 k	742 k	1.4 m	1.6 m
Accounts Receivable	(32 m)	31.6 m	1.8 m	239 k
Inventories	(1.5 m)	(419 k)	(1.6 m)	(1.5 m)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	(20.3 m)	(40 m)	(61.3 m)	(25.8 m)	(23.1 m)	(22.9 m)	(28 m)	(24.3 m)	(32.5 m)
Depreciation and Amortization	362 k	548 k	260 k			389 k
Accounts Receivable	31.5 m	31.6 m	1.7 m	723 k	177 k	86 k	60 k	6.2 m	8 k
Accounts Payable	(142 k)	1.1 m	(3.2 m)	3 m	3 m	(2.4 m)	3.7 m	3.4 m	7.3 m